glp 1 inhibitors moa “Weighing In” on GLP-1 Receptor Agonists for People With HIV The Role of GLP-1RA Medications

If GLP-1 medications eventually prove beneficial for endo, they'd be an add-on to that toolkit, not a replacement for it

CAMP participants were considered typically developing (TYP) if the MSEL DQ was greater than 70 and the participant did not receive a diagnosis of developmental delay or autism

April 30, 2026: The bulks-list pathway is now proposed to be closed permanently

(Melanotan II does not have established clinical use.) I think there is a reasonable possibility that the regulatory landscape surrounding some peptides may become more permissive, particularly within physician-supervised or compounding settings, she explains

The Observational Health Data Sciences and Informatics (OHDSI) network conducted an expansive analysis encompassing 37.1 million adults with Type 2 diabetes across 14 international databases, published in February 2025

Ready for a positive change